Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bupropion SR Clear all
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 2, 2026, 3:59 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

NCT05732272
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 2, 2026, 3:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Symptom Burden in Head and Neck Cancer

NCT01219673
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Placebo, Armodafinil, Minocycline, Bupropion
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

NCT02162862
View directory record Official record
Conditions
Sleep Disturbance, Fatigue, Inflammatory Bowel Disease
Interventions
Behavioral Counseling, bupropion-SR
Behavioral · Drug
Lead sponsor
Eva Szigethy
Other
Eligibility
15 Years to 30 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Maintenance Treatment for Smoking Cessation

NCT01615770
View directory record Official record
Conditions
Smoking
Interventions
cognitive behavior therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 2, 2026, 3:59 AM EDT
Not listed Phase 2 Interventional

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

NCT04971291
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
AXS-05, Bupropion SR
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Bupropion in the Treatment of Methamphetamine Dependence

NCT00572234
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
bupropion SR
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Maintenance Treatment for Abstinent Smokers

NCT00063323
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 75 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

NCT00865111
View directory record Official record
Conditions
Healthy
Interventions
Bupropion 150 mg Extended-Released Tablet, single dose, Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2010 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dynamic Measures of Neurochemistry in Mood Disorders

NCT00178828
View directory record Official record
Conditions
Depression
Interventions
sertraline, bupropion
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

NCT00129272
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder
Interventions
Bupropion-SR, Placebo
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
12 Years to 25 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

NCT00865410
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2010 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bupropion SR Plus Counseling for Smoking Cessation

NCT01621009
View directory record Official record
Conditions
Tobacco Dependence, Smoking
Interventions
Active bupropion + counseling, Active bupropion, No counseling, Placebo medication + counseling, Placebo medication, No counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Results available

Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)

NCT00285584
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Bupropion, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

NCT00129246
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Naltrexone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Results available

Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers

NCT02245308
View directory record Official record
Conditions
Tobacco Use Disorder, Homelessness
Interventions
Nicotine Patches, mobile contingency management (mCM), Smoking cessation counseling, Nicotine rescue method, Bupropion
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

NCT00339014
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide CR and Bupropion SR, Placebo
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

NCT03045341
View directory record Official record
Conditions
Binge-eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Varenicline and Bupropion for Smoking Cessation

NCT00935818
View directory record Official record
Conditions
Smoking
Interventions
Varenicline, placebo, bupropion SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Minneapolis, Minnesota • Rochester, Minnesota • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Mood and Marriage Study (TOMMS)

NCT00612807
View directory record Official record
Conditions
Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions
Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

VA Augmentation and Switching Treatments for Improving Depression Outcomes

NCT01421342
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 2, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

NCT00624858
View directory record Official record
Conditions
Depression
Interventions
naltrexone SR 32 mg/ bupropion SR 360 mg daily
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 2, 2026, 3:59 AM EDT